

A-Engrossed
House Bill 3817

Ordered by the House April 16
Including House Amendments dated April 16

Sponsored by Representative SKARLATOS, Senator SMITH DB; Representatives CHOTZEN, HARBICK, LEWIS, LIVELY, RESCHKE, Senators STARR, THATCHER

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure. The statement includes a measure digest written in compliance with applicable readability standards.

Digest: The Act tells OHA and DVA to study the use of ibogaine by some people to help treat certain disorders. (Flesch Readability Score: 68.0).

[Digest: The Act tells OHA and DVA to set up a process to let a person with a certain disorder use ibogaine to help treat the disorder. (Flesch Readability Score: 63.3).]

Directs the Oregon Health Authority *[in collaboration with]* **and** the Department of Veterans' Affairs to *[establish a process through which a certain individual may consume ibogaine for a specified purpose]* **study the consumption of ibogaine by certain individuals for the purpose of treating specified disorders.** Defines "ibogaine." Requires the authority and the department to submit a report to the interim committees of the Legislative Assembly related to health care *[and veterans]* not later than September 15, 2029. *[Exempts ibogaine, when obtained and consumed through the established process, from the definition of "controlled substance."]*

Sunset on January 2, 2030.

A BILL FOR AN ACT

1
2 Relating to ibogaine.

3 **Be It Enacted by the People of the State of Oregon:**

4 **SECTION 1. (1) As used in this section, "ibogaine" means a naturally occurring indole**
5 **alkaloid extracted from the root bark of the Tabernanthe iboga shrub.**

6 **(2) The Oregon Health Authority and the Department of Veterans' Affairs shall study the**
7 **consumption of ibogaine by individuals who have post-traumatic stress disorder, major**
8 **depressive disorder, an anxiety disorder or substance use disorder for the purpose of treating**
9 **the disorder. The authority and the department shall submit a report in the manner provided**
10 **by ORS 192.245, and may include recommendations for legislation, to the interim committees**
11 **of the Legislative Assembly related to health care no later than September 15, 2029. The re-**
12 **port must include information about and recommendations on the following:**

13 **(a) The available medical, psychological and scientific studies, research and other data**
14 **relating to the safety and efficacy of ibogaine;**

15 **(b) The sourcing and production of ibogaine;**

16 **(c) Recommended doses and delivery methods of ibogaine;**

17 **(d) Testing and safety of ibogaine products;**

18 **(e) Best practices for client and public health and safety, including client data protection**
19 **and client consent;**

20 **(f) Training and requirements for individuals who administer ibogaine to clients;**

21 **(g) Requirements for how ibogaine is administered to clients and how clients are prepared**
22 **and supported through the duration of and after administration;**

NOTE: Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted. New sections are in **boldfaced** type.

1 **(h) Requirements for a system to track ibogaine and locations at which ibogaine will be**
2 **produced, stored and administered or consumed;**

3 **(i) Client screening and eligibility requirements for consumption of ibogaine, and any**
4 **conditions that would cause a client to be ineligible;**

5 **(j) Funding mechanisms for the administration of an ibogaine program and the long-term**
6 **sustainability of the program; and**

7 **(k) Reporting of data on ibogaine consumption and client outcomes.**

8 **SECTION 2.** Section 1 of this 2025 Act is repealed on January 2, 2030.

9